Morphosys AG Return on Equity

Morphosys AG (MOR) currently reports a ROE of 175.9%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Morphosys AG's ROE history and peer comparisons.

Morphosys AG's ROE of 175.9% is higher than the Healthcare sector average of 22.76%. That is roughly 672.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Morphosys AG's current 175.9% should be judged against Healthcare norms (sector average: 22.76%) and against MOR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 175.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Morphosys AG, and consider following MOR for alerts when major investors trade the stock.

Morphosys AG is classified in the Healthcare sector. On ROE, it currently shows 175.9% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MOR with unrelated industries.